Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer

Autor: Thomas Bachelot, Paul Cottu, Sylvie Chabaud, Florence Dalenc, Djelila Allouache, Suzette Delaloge, Jean-Philippe Jacquin, Julien Grenier, Laurence Venat Bouvet, Apurna Jegannathen, Mario Campone, Francesco Del Piano, Marc Debled, Anne-Claire Hardy-Bessard, Sylvie Giacchetti, Marie-Ange Mouret-Reynier, Philippe Barthelemy, Laure Kaluzinski, Audrey Mailliez, Eric Legouffe, Matthew Sephton, Judith Bliss, Jean-Luc Canon, Frederique Penault-Llorca, Jerome Lemonnier, David Cameron, Fabrice Andre

Publikováno v: Journal of Clinical Oncology
Journal of Clinical Oncology, 2022, 40 (32), pp.3699-3708. ⟨10.1200/JCO.21.02179⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, In press, ⟨10.1200/JCO.21.02179⟩
Bachelot, T, Cottu, P, Chabaud, S, Dalenc, F, Allouache, D, Delaloge, S, Jacquin, J-P, Grenier, J, Venat Bouvet, L, Jegannathen, A, Campone, M, Del Piano, F, Debled, M, Hardy-Bessard, A-C, Giacchetti, S, Mouret-Reynier, M-A, Barthelemy, P, Kaluzinski, L, Mailliez, A, Legouffe, E, Sephton, M, Bliss, J, Canon, J-L, Penault-Llorca, F, Lemonnier, J, Cameron, D A & Andre, F 2022, ' Everolimus added to adjuvant endocrine therapy in patients with high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer ', Journal of Clinical Oncology, vol. 386, JCO.21.02179 . https://doi.org/10.1200/JCO.21.02179, https://doi.org/10.1200/JCO.21.02179

PURPOSE Everolimus, an oral inhibitor of the mammalian target of rapamycin, improves progression-free survival in combination with endocrine therapy (ET) in postmenopausal women with aromatase inhibitor–resistant metastatic breast cancer. However,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::574c2bb7629f4cc70b7bae1bbc69bd0b
https://hal.archives-ouvertes.fr/hal-03857432